autologous NY-ESO-1-specific CD8-positive T lymphocytes
Term · Oncology and biomedicine · MLC-T-ONC-011727
A preparation of autologous CD8+ T lymphocytes specifically reactive to the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Autologous NY-ESO-1-specific CD8+ T lymphocytes were generated from T cells isolated from a particular cancer patient, which were made specifically reactive to the NY-ESO-1 antigen, expanded ex vivo, and reintroduced into the patient. These tumor-reactive T cells may stimulate a host immune response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, may be upregulated in various cancers.
| Identifier | MLC-T-ONC-011727 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011727",
"term": "autologous NY-ESO-1-specific CD8-positive T lymphocytes",
"field": "Oncology and biomedicine",
"definition": "A preparation of autologous CD8+ T lymphocytes specifically reactive to the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Autologous NY-ESO-1-specific CD8+ T lymphocytes were generated from T cells isolated from a particular cancer patient, which were made specifically reactive to the NY-ESO-1 antigen, expanded ex vivo, and reintroduced into the patient. These tumor-reactive T cells may stimulate a host immune response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, may be upregulated in various cancers.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-ny-eso-1-specific-cd8-positive-t-lymphocytes/"
}
Record 3,063 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.